Maxim Group analyst Jason Kolbert reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8.00 price target, as the company announced completion of the dose escalation …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on shares of Biolinerx (NASDAQ:BLRX) and raised …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Biolinerx (NASDAQ:BLRX) and raised his price target to $10.50 …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Biolinerx (NASDAQ:BLRX) with a $7.00 price target, as …
Maxim analyst Jason Kolbert reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with a price target of $7.00, as the company has completed its BL-7010 …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reaffirmed a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8 price target, …
In a research report released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8 price target. The …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8 price target, …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Biolinerx (NASDAQ:BLRX) with a $7.00 price target, following the …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with a price target of …
